Compare MATH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | MCRB |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 41.2M |
| IPO Year | 2016 | 2015 |
| Metric | MATH | MCRB |
|---|---|---|
| Price | $1.04 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 29.1K | ★ 82.3K |
| Earning Date | 08-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | $1,648.67 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.30 |
| 52 Week High | $3.19 | $29.98 |
| Indicator | MATH | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 23.16 |
| Support Level | $0.93 | N/A |
| Resistance Level | $1.13 | $2.26 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 60.26 | 11.46 |
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.